Umbralisib plus ublituximab vs. standard of care chemoimmunotherapy in CLL
Ian Flinn • 7 Dec 2020
Are combination therapies more effective for the treatment of relapsed refractory CLL?
Cord blood-derived NK cells with high-dose chemotherapy & ASCT for B-NHL
Yago Nieto • 15 Feb 2021